Lightcast, a company focused on antibody discovery, has secured $27 million in a follow-on financing round from its existing investor base. This capital infusion will support the company's ongoing efforts to advance its antibody discovery platform. The specific details regarding client numbers, revenue, pipeline, or employee count were not disclosed in the announcement.
